1-5 of 5
Jue Wang, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Naval G. Daver, MD, Jacqueline S Garcia, MD, Brian A Jonas, MD PhD, Kevin R Kelly, MD PhD, Sarit Assouline, MD, Joseph M Brandwein, MD, Pierre Fenaux, MD PhD, Rebecca L. Olin, MD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Arnaud Pigneux, Daniel A Pollyea, MD, Bayard L Powell, MD, Gail J. Roboz, MD, Agostino Tafuri, MD, Norbert Vey, MD PhD, Giuseppe Visani, MD, Karen W.L. Yee, MD, Monique Dail, PhD, Cherie Green, BS, Whitney P Kirschbrown, PharmD, PhD, Wan-Jen Hong, MD, Marion G Ott, MD PhD, Maika Onishi, MD, Jue Wang, PhD, Marina Y Konopleva, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 229.
https://doi.org/10.1182/blood-2019-123711
Published: 2019
Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Barbara F. Eichhorst, MD, Peter Hillmen, MD PhD, James D'Rozario, MBBS, FRACP, FRCPA, Sarit Assouline, MD, Carolyn Owen, MD, Tadeusz Robak, MD, Javier de la Serna, MD PhD, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Su Young Kim, MD PhD, Jenny Wu, MS, Yanwen Jiang, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Arnon P Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 355.
https://doi.org/10.1182/blood-2019-123930
Published: 2019
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

Alterations in Sphingomyelin Metabolism Influences Tissue Factor Procoagulant Activity and the Release of TF-Positive Microvesicles

Jue Wang, PhD, Usha Pendurthi, PhD, L. Vijaya Mohan Rao, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1103.
https://doi.org/10.1182/blood-2019-125933
Published: 2019
Journal Articles

The Role of Sphingomyelin (SM) in Tissue Factor (TF) Encryption: ATP-Induced Activation of Acid Sphingomyelinase in Macrophages Decrypts Tissue Factor By Hydrolysis of SM in the Outer Leaflet

Jue Wang, PhD, Usha R Pendurthi, PhD, L. Vijaya Mohan Rao, PhD
Journal: Blood
Blood (2016) 128 (22): 16.
https://doi.org/10.1182/blood.V128.22.16.16
Published: 2016